Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
Results were consistent with the primary analysis despite increased use of subsequent systemic anticancer therapy and crossover to lenvatinib+pembrolizumab in the chemotherapy group. The continued durable benefit, including OS, with lenvatinib+pembrolizumab and no new safety signals lend further support for this regimen as a standard of care therapy for EC.
Authors
- Shiro Suzuki
- Ronnie Shapira-Frommer
- Chinyere E. Okpara (ORCID: https://orcid.org/0000-0002-5621-9138)
- K. Fujiwara
- Alexandra Sebastianelli
- F. Selle
- Rebecca Kristeleit (ORCID: https://orcid.org/0000-0003-3825-1326)
- S. Nishio (ORCID: https://orcid.org/0000-0003-2659-5930)
- Vicky Makker
- U A Sanli
- Stephan Kruger
- I. Ray-Coquard
- Zafer ARIK
- Domenica Lorusso
- Alessandro D. Santin
- Zhou Yu
- Yong Man Kim
- Ayumi Shikama
- Ali Arican
- Antonio Casado
- Emeline Colomba
- Robin Meng
- Jodi McKenzie
- Nicoletta Colombo
- David S Miller
- Jorge L Martínez Rodríguez
- Eva M Guerra Alía
- Sandro Pignata
- Kan Yonemori
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Kurume University (JP)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Humanitas University (IT)
- University of Tsukuba (JP)
- Mario Negri Institute for Pharmacological Research (IT)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Cornell University (US)
- Sheba Medical Center (IL)
- Royal North Shore Hospital (AU)
- Asan Medical Center (KR)
- Institut Gustave Roussy (FR)
- Hospital Clínico San Carlos (ES)
- Yale University (US)
- University of Ulsan (KR)
- Ege University (TR)
- Centre Léon Bérard (FR)
- Groupe Hospitalier Diaconesses Croix Saint-Simon (FR)
- Decision Sciences (United States) (US)
- Aichi Cancer Center (JP)
- Acıbadem University Atakent Hospital (TR)
- Centre hospitalier de l'Université Laval (CA)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- The Society of Gynecologic Oncology of Canada (CA)
- National Cancer Center Hospital East (JP)
- Eisai (United Kingdom) (GB)
- Hospital Universitario Ramón y Cajal (ES)
- IRCCS Humanitas Research Hospital (IT)
- Université Laval (CA)
- Eisai (Japan) (JP)
- European Institute of Oncology (IT)
- Hacettepe University (TR)
- University of Milano-Bicocca (IT)
- Saitama Medical University (JP)
- The University of Texas Southwestern Medical Center (US)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013713
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eisai